In a landmark ruling in one of the world’s fastest growing pharmaceutical markets, the Intellectual Property Appellate Board (IPAB) of India upheld the compulsory licence granted to Natco Pharma Limited, an Indian drug manufacturer, for Bayer AG’s Nexavar (sorafenib tosylate), an oncology palliative drug.